Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab
- 1 August 2005
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 153 (2), 449-451
- https://doi.org/10.1111/j.1365-2133.2005.06740.x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemiaBone Marrow Transplantation, 2004
- Anti B cell therapy (rituximab) in the treatment of autoimmune diseasesCurrent Opinion in Pharmacology, 2004
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- GuidelinesBritish Journal of Dermatology, 2003
- Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigusBritish Journal of Dermatology, 2003
- Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)British Journal of Dermatology, 2003
- Mechanism of action of rituximabAnti-Cancer Drugs, 2002
- Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorderJournal of the American Academy of Dermatology, 2002
- Treatment of childhood autoimmune haemolytic anaemia with rituximabThe Lancet, 2001
- Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins.The Journal of Immunology, 1997